Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias

Acta Haematol (2015) 134 (4): 233–242.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

MSCT and MRI indicators for assessing iron overload and the effectiveness of iron overload therapy in patients with primary and secondary hemochromatoses

A. M. Titova
V. A. Fokin
G. E. Trufanov
M. A. Zubkov
A. V. Nikitina
R. R. Mironchuk
M. V. Mironchuk
N. V. Tsvetkova
K. S. Shalygina
L. E. Galyautdinova
M. V. Lukin
Z. F. Badrieva

Medical Visualization (2023) 27 (4): 170.

Dose of deferasirox correlates with its effects, which differ between low‐risk myelodysplastic syndrome and aplastic anaemia

Ruoxi Zhang
Bing Han

Journal of Clinical Pharmacy and Therapeutics (2022) 47 (10): 1619.

Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan

Bor-Sheng Ko
Ming-Chih Chang
Tzeon-Jye Chiou
Te-Kau Chang
Yeu-Chin Chen
Sheng-Fung Lin
Cheng-Shyong Chang
Yin-Che Lu
Su-Peng Yeh
Tsai-Yun Chen
Wei-Shou Hwang

Hematology (2019) 24 (1): 247.

Protective Effect of Astragaloside IV on Hepatic Injury Induced by Iron Overload

Dongyu Xie
Ping Zhou
Lin Liu
Wenjing Jiang
Haina Xie
Liang Zhang
Donghao Xie

BioMed Research International (2019) 2019: 1.

Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET

Angela Vitrano
Massimiliano Sacco
Rosamaria Rosso
Alessandra Quota
Daniela Fiorino
Esther Oliva
Calogera Gerardi
Gaetano Roccamo
Vincenzo Spadola
Aldo Filosa
Lorenzo Tesé
Giuseppina Calvaruso
Lorella Pitrolo
Laura Mistretta
Filippo Cassarà
Rosario Di Maggio
Aurelio Maggio

European Journal of Haematology (2018) 100 (2): 124.

Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy

Jamile M. Shammo
Rami S. Komrokji

Expert Review of Hematology (2018) 11 (7): 577.

Iron‐chelating therapy with deferasirox in transfusion‐dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study

Pellegrino Musto
Luca Maurillo
Vittorio Simeon
Antonella Poloni
Carlo Finelli
Enrico Balleari
Alessandra Ricco
Flavia Rivellini
Agostino Cortelezzi
Giuseppe Tarantini
Oreste Villani
Giovanna Mansueto
Maria R. Milella
Daniele Scapicchio
Gioacchino Marziano
Massimo Breccia
Pasquale Niscola
Alessandro Sanna
Cristina Clissa
Maria T. Voso
Susanna Fenu
Adriano Venditti
Valeria Santini
Emanuele Angelucci
Alessandro Levis

British Journal of Haematology (2017) 177 (5): 741.

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma

Issei Saeki
Naoki Yamamoto
Takahiro Yamasaki
Taro Takami
Masaki Maeda
Koichi Fujisawa
Takuya Iwamoto
Toshihiko Matsumoto
Isao Hidaka
Tsuyoshi Ishikawa
Koichi Uchida
Kenji Tani
Isao Sakaida

World Journal of Gastroenterology (2016) 22 (40): 8967.

Another Step Forward in Iron Chelation Therapy

Emanuele Angelucci

Acta Haematologica (2015) 134 (4): 231.